edaravone + dextromethorphan

Edaravone + dextromethorphan is a hypothetical or investigational combination of two small molecule drugs, each with distinct mechanisms of action and approved uses. Edaravone is a free radical scavenger primarily indicated for the treatment of amyotrophic lateral sclerosis (ALS) and acute ischemic stroke. It acts by reducing oxidative stress through neutralization of reactive oxygen species, thereby protecting neurons from damage[6][9][10]. Dextromethorphan is an antitussive agent commonly used as a cough suppressant and also approved in combination with other agents for pseudobulbar affect and major depressive disorder. Its mechanisms include noncompetitive antagonism at NMDA receptors, agonism at sigma-1 receptors, inhibition of serotonin reuptake, and antagonism at certain nicotinic acetylcholine receptors[5][8]. There are currently no known marketed products or clinical trial data specifically for the fixed-dose combination "edaravone + dextromethorphan," but both drugs have established roles in neuroprotection and neuromodulation.